Two-Year Intention-to-Treat Analysis for Tumor Outcome in Patients Treated with Avasopasem for Oral Cavity and Oral Pharynx Primaries

IMRT plus cisplatin (CRT) is established treatment for LAHNC, but ∼70% of patients develop severe oral mucositis (SOM), often requiring feeding tube nutrition. Avasopasem (AVA) is an investigational small molecule selective dismutase mimetic converting superoxide to hydrogen peroxide, which may protect normal cells from, and potentially sensitize cancer cells to , RT (Anderson 2019, Sishc 2021). In a randomized, double-blind phase 3 trial, AVA substantially reduced duration and incidence of SOM versus placebo (PBO) without an adverse effect on safety or 1-yr survival (Anderson 2022).

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.E. Dunlap, C.M. Lee, J.R. Kelley, G.V. Walker, V. Bar-Ad, D.A. Miller, V.J. King Sr, A.V. Peddada, D. Ciuba, F. Vincent, B.C. Muzyka, A.L. Gillespie-Twardy, S.T. Sonis, J. Holmlund, D. Saunders, R. Beardsley, C.M. Anderson Tags: 11 Source Type: research